rarediseases.org Open in urlscan Pro
141.193.213.20 Public Scan

Back to summary

URL:
https://rarediseases.org/rare-diseases/paraneoplastic-neurologic-syndromes/
Submission: On January 20 via api (January 20th 2022, 6:09:30 pm UTC) from US — Scanned from DE

Form analysis
1 forms found in the DOM

GET /

<form method="get" id="searchform_header" action="/"> <input type="text" class="form-control" name="s" id="s" placeholder="Search"> <input type="submit" class="btn btn-default" name="submit" id="searchsubmit" value=""></form>

Text Content

Scroll
To Top
* About
* News
* Events
* Contact
* PODCAST
* Store

donate
Advanced Search

Menu
* for Patients and Families
* Information & Resources
* Rare Disease Information
* Rare Disease Video Library
* Patient and Caregiver Resource Center
* Information on Clinical Trials and Research Studies
* Rare Disease Centers of Excellence
* COVID-19 Resources
* Help to Access Medications
* Patient Assistance Programs
* Other Financial Assistance
* Connect with Others
* Find a Patient Organization
* Rare Disease Day®
* Patient Stories
* Take Action
* Attend Events
* Advocate
* Support
* Close
* for Patient Organizations
* Join Membership Network
* Value of Membership
* Membership Criteria
* Apply for Membership
* Nonprofit
Resources
* Membership Benefits
* Membership Resources
* RareLaunch®
* Webinar Series
* COVID-19 Rapid Response Leadership Series
* Other Ways to Partner
* Grow your organization
* Patient Registries
* Advocacy
* Rare Disease Day®
* RDCA-DAP®
* Membership Profiles
* About our Members
* Member List
* Rare Cancer Coalition™
* Close
* for Clinicians and Researchers
* Resources
* Resources for Medical Professionals
* Rare Disease Information
* Resources for your Patients
* Continuing Medical Education
* Research Opportunities
* Research Grant Program
* Requests for Proposals
* Research Grant Recipients
* Connect
* Lend Your Expertise
* Rare Disease Day®
* Close
* NORD Rare Disease Advocacy
* NORD’s Policy in Action
* Issue Overviews
* NORD on the Issues
* Policy Steering Committee
* NORD State Report Card
* National Partnerships
* Take Action Locally
* Join the Rare Action Network®
* Project RDAC
* Contact Your Representatives
* Take Action
* RareInsights®
* RareInsights®
* 5 Myths About Orphan Drugs and the Orphan Drug Act
* Close
* Get Involved
* Donate Now
* Give
* Ways to Give
* Donate to Research
* NORD® Store
* Educate
* Educational Initiatives
* Raise Awareness
* Identify Rare Disease Experts
* Join
* Participate in Events
* Become a Member
* Rare Cancer Coalition™
* Employment Opportunities
* Corporate Council
* About the Corporate Council
* Current Members
* Council Code of Conduct
* Join the Council
* Close

Home / For Patients and Families / Rare Disease Information / Paraneoplastic
Neurologic Syndromes

RARE DISEASE DATABASE

0-9• A• B• C• D• E• F• G• H• I• J• K• L• M• N• O• P• Q• R• S• T• U• V• W• X• Y•
Z
Print

PARANEOPLASTIC NEUROLOGIC SYNDROMES

NORD gratefully acknowledges Josep Dalmau, MD, PhD, Research Professor, ICREA
(Catalan Institution of Research and Advanced Studies) and IDIBAPS (Institution
for Biomedical Research August Pi i Sunyer); Hospital Clinic, University of
Barcelona, Spain; Adjunct Professor, Neurology, University of Pennsylvania, for
assistance in the preparation of this report.

GENERAL DISCUSSION

Paraneoplastic neurologic syndromes (PNS) are a group of conditions that affect
the nervous system (brain, spinal cord, nerves and/or muscles) in patients with
cancer. The term “paraneoplastic” means that the neurological syndrome is not
caused by the tumor itself, but by the immunological reactions that the tumor
produces. It is believed that the body’s normal immunological system interprets
the tumor as an invasion. When this occurs, the immunological system mounts an
immune response, utilizing antibodies and lymphocytes to fight the tumor. The
end result is that the patient’s own immune system can cause collateral damage
to the nervous system, which can sometimes be severe. In many patients, the
immune response can cause nervous system damage that far exceeds the damage done
to the tumor. The effects of PNS can remit entirely, although there can also be
permanent effects.

SIGNS & SYMPTOMS

Paraneoplastic neurologic syndromes can manifest themselves in different ways,
such as encephalitis (inflammation of the brain), ataxia (loss of balance),
neuropathy (progressive numbness/ weakness of feet and hands),
myoclonus/opsoclonus (body jerks and irregular rapid eye movements), psychiatric
disturbances, or myasthenia gravis (a neuromuscular disorder that causes extreme
weakness of several muscle groups, including those that control breathing). It
is the presence of specific paraneoplastic antibodies that often leads to the
diagnosis of a paraneoplastic neurologic syndrome.

Symptoms of PNS can develop rapidly, over the course of a few days or weeks, or
they may develop slowly. Often, they seem to follow what may appear to have been
a transient viral illness. In about 60% of patients with PNS, the symptoms occur
before the diagnosis of cancer is made. For about 40% of patients already known
to have cancer, the initial symptoms of PNS may appear to resemble other
complications of cancer. In addition, some cancer treatments can also cause
neurological symptoms that can be mistaken for PNS.

PNS can frequently appear to affect only a single area of the nervous system. In
some cases of PNS, only one area of the nervous system is involved initially,
but over time, other areas can become affected. Therefore, careful and repeated
neurologic examinations are required to follow and monitor the disease process.

In the majority of patients with PNS, the tumor is localized to one site without
having metastasized (spread) to distant parts of the body. Usually, the size of
the tumor at this stage is small. For this reason, it can be very difficult to
find the tumor. The combination of symptoms, lab studies, and the paraneoplastic
antibodies that may be found in the blood and/or spinal fluid, helps to make the
diagnosis of a paraneoplastic neurologic syndrome. The specific antibodies, if
detected, can help focus the search for the tumor to one or a few organs.

Broadly speaking, paraneoplastic neurologic syndromes (PNS) are categorized by
(1) the area of the nervous system that is principally affected; (2) the type of
symptoms manifested; or (3) the type of immunological response.

Paraneoplastic Limbic Encephalitis

This disorder results from an inflammation of the brain and, in particular, the
limbic system, which includes the hippocampus, amygdala, hypothalamus, and
several other related areas. This part of the brain is involved in memory,
emotion and behavior, and controls reactions of fear and anger. It can also
involve the emotions of sexual behavior. The hypothalamus participates in the
functioning of the autonomic nervous system, which regulates bodily functions
such as blood pressure control, heart rate, pupil reactivity, endocrine/hormone
function, body temperature, food and water intake, and sleeping and wakefulness.
These functions can each be adversely affected in the setting of any type of
encephalitis.

A variety of symptoms can result from paraneoplastic limbic encephalitis, such
as mood changes, problems sleeping, and severe, short-term memory deficits. In
addition, many patients with limbic encephalitis develop seizures or
seizure-like spells, or sometimes grand mal seizures resulting in a total loss
of consciousness.

The combination of clinical symptoms, analysis of blood and spinal fluid, and
brain MRI and EEG findings can suggest the diagnosis of limbic encephalitis.
However, it is the specific presence of paraneoplastic antibodies (in
particular, Hu, Ma2, and CRMP5, NMDA receptor, GABA(B) receptor, AMPA receptor,
Caspr2, mGluR5 antibodies) in the blood and/or spinal fluid that usually forms
the diagnosis of paraneoplastic limbic encephalitis.

The cancers more often associated with paraneoplastic limbic encephalitis are
cancers of the lung and testis and tumors of the thymus (thymoma) although other
cancers can also be involved.

Symptoms identical to paraneoplastic limbic encephalitis may occur without
cancer; these patients often have antibodies to LGI1 (previously known as
voltage-gated potassium channel antibodies or VGKC).

Paraneoplastic Cerebellar Degeneration

Patients with this form of PNS develop severe problems in fine motor
coordination of the arms, legs, and the muscles that control the eyes, speech
and swallowing. In general, all movements will become fragmented and a tremor
(shaking of the hands) may develop. Due to problems controlling the movement of
the eyes, patients develop double vision or a sensation of “jumpiness” of the
visual field (“opscillopsia”). Ordinary activities such as reading or watching
TV can become difficult or impossible, and simple chores like writing, feeding
oneself or dressing can also become impossible to perform.

The brain MRI, at the onset of this type of PNS, can appear normal. However,
several months after the presentation of neurological symptoms, the brain MRI
will usually show atrophy (shrinkage) of the cerebellum.

Several different paraneoplastic antibodies have been associated with
paraneoplastic cerebellar degeneration, including among others Yo, Tr, or mGluR1
antibodies. The associated tumors include, but are not limited to, gynecologic
cancers (mainly ovarian cancer), breast, lung, and Hodgkin’s lymphoma.

Paraneoplastic cerebellar degeneration is one of the most difficult of the PNS
to treat. Although there may be some mild improvement after treatment of the
primary tumor, the majority of patients do not improve. Treatment may result in
stabilization of symptoms. In very rare instances, dramatic improvements can
occur.

Paraneoplastic Encephalomyelitis

This disorder affects multiple areas of the brain, cerebellum, brainstem and
spinal cord.

Patients with paraneoplastic encephalomyelitis usually develop symptoms or
deficits that combine those found in both “limbic encephalitis” and “cerebellar
degeneration” In addition, due to involvement of the brainstem, patients may
develop double or blurry vision, slurred speech, vertigo and/or dizziness,
changes in heart rhythms, tremor, and slow movements. The symptoms may initially
resemble Parkinson’s disease, and can progress to loss of consciousness and
coma. There can also be a malfunction of the nerves that carry information and
signals to and from the brain/arms/legs.

Depending upon which of the paraneoplastic antibodies is present, some patients
may develop difficulty in moving the lips. When they try to talk, their voice
may be barely audible to the point that they may appear mute. However, they are
able to understand other people and answer commands with signals, such as with a
thumbs up or down.

When the affected patient is a man younger than 50 years, the tumor is often in
the testis. If the patient, male or female, is older than 50 years, the
associated tumor is likely to be in the lung or other part of the body.

Various paraneoplastic antibodies are associated with paraneoplastic
encephalomyelitis, including Hu, CRMP5, Ma2, and amphiphysin.

Prompt diagnosis of this type paraneoplastic encephalomyelitis is important
because some patients improve with treatment.

Paraneoplastic Encephalitis associated with anti-NMDAR Antibodies

This syndrome usually affects teenagers or young women in whom other diseases or
problems are frequently suspected. Many of these young patients will at first be
thought to be manifesting either an acute psychiatric process or a drug abuse
reaction. In general, the progression of severe symptoms leads the practitioner
to the suspect the patient has an encephalitis.

The symptoms may include anxiety, insomnia, mood changes, bizarre behavior,
delusions/hallucinations, episodes of near catatonia (absence of movement),
episodes of mumbling or talking gibberish, and/or confusion. Over the course of
time, fine muscle twitching can progress to more pronounced abnormal movements
and postures of the arms and legs (choreoathetosis). Many patients develop
abnormal movements with the face, mouth or tongue (orofacial dyskinesias).
Autonomic nervous system dysfunction becomes apparent, and a high temperature
(as a result of autonomic dysfunction) can occur, leading to suspect an
infection.

This type of encephalitis can be paraneoplastic or not. When paraneoplastic the
most common tumor found is a teratoma. The presence of a tumor varies according
to the age of the patient, sex, and ethnicity. For example, about 50% of young
women (between 18 years and 45 years) have an ovarian teratoma. Older women and
men may have other types of tumors or cancer. In contrast, most children
(younger than 12 years) male or female, do not have a tumor. Removal of the
tumor (when identified) and immunotherapy result in decreased levels of NMDAR
antibodies, and improvement or full neurological recovery.

In summary, the encephalitis associated with anti-NMDAR antibodies is one of the
most commonly identified autoimmune encephalitis and can occur as a
paraneoplastic or non-paraneoplastic disorder. Both forms of encephalitis are
highly responsive to immunotherapy and tumor removal (if present).

Paraneoplastic Stiff-Person Syndrome

This type of PNS presents as muscle stiffness and rigidity, along with painful
spasms. The symptoms usually present in the muscles of the lower back and legs,
but may also affect the arms and legs, and then progress to affect other parts
of the body. The spasms can be enhanced or triggered by anxiety, loud noises, or
simply by touch or trying to move.

Paraneoplastic stiff-person syndrome should not be confused with the
non-paraneoplastic form of stiff-person syndrome. When the disorder is the
paraneoplastic type, a specific antibody called anti-amphiphysin is usually
found in the blood and spinal fluid of the patient. The tumors usually
associated with this PNS are cancer of the breast or lung.

Patients with non-paraneoplastic stiff-person syndrome more often develop other
type of antibodies, such as GAD or Glycine receptor (GlyR) antibodies. In rare
instances, these antibodies can also occur in patients with paraneoplastic
stiff-person syndrome.

Paraneoplastic Opsoclonus-Myoclonus or Opsoclonus-Ataxia

Opsoclonus is a neurological symptom in which the patient’s eyes move rapidly
from one direction to another in an uncontrolled fashion. Myoclonus is a
neurological symptom of uncontrolled muscle body jerks that can affect the face,
arms or legs. Ataxia is a neurological symptom of difficulty controlling the
muscles of the trunk and or arms or legs, leading to an uncoordinated, swerving
gait. These symptoms can affect children or adults.

In children, opsoclonus is the most common paraneoplastic syndrome. It usually
affects patients younger than four years of age, and presents with sudden
development of staggering and falling (ataxia) often followed by body jerks,
drooling, refusal to walk or sit, opsoclonus, irritability and sleep
disburbances. The associated tumor is neuroblastoma (about 50% of children with
similar symptoms do not have a tumor). Although symptoms may resolve or improve
after treatment of the tumor and immunotherapy, many children are left with
behavioral abnormalities and other developmental abnormalities.

While no specific antibody has been identified for pediatric paraneoplastic
opsoclonus-myoclonus, there is a large amount of evidence that as-of-yet
unidentified antibodies are involved.

In adults with opsoclonus-myoclonus, there are usually fewer behavioral
abnormalities, but ataxia is often prominent. The cancers most often associated
with these symptoms in adults are usually located in the lung, breast, and
ovary. Sometimes, in approximately 20% of adults with this disorder, well-known
paraneoplastic antibodies are discovered. The best known of these antibodies is
called “anti-Ri”.

Treatment of the tumor and immunotherapy usually results in improvement or
stabilization of the neurologic symptoms.

Sensory Neuronopathy

This term refers to the neurons from which the sensory nerves originate. These
neurons are clustered in the “dorsal root ganglia” which are located along the
sensory nerve roots close to the spinal cord.

Symptoms of sensory neuronopathy usually start in an asymmetric fashion. That
is, they will begin on one side, and in a matter of days and weeks progress to
involve the other side, eventually becoming symmetric. The symptoms most
frequently described by patients include lancinating pain (short-lasting,
electric shock type pain), a sensation of walking on sand, cold, numbness, or a
feeling of burning in hands and feet. Sensations in the face, as well as the
taste and hearing, can be affected. In the advanced stage of sensory
neuronopathy, all sensations can be severely diminished or lost. Sensory ataxia
can occur, which diminishes the ability to know where the limbs are when the
eyes are closed, making it difficult to reach out for something or to walk.

The antibodies most often associated with paraneoplastic sensory neuronopathy
are the “anti-Hu” antibodies. There is often an association with small-cell lung
cancer, although other cancers can be associated.

Paraneoplastic Neuropathies
There are two main types of peripheral nerves: motor and sensory. Motor nerves
make the muscles move and are important in muscle strength. Sensory nerves allow
for the feeling of different sensations, such as touch, pain, heat, cold and
vibration. Most neuropathies affect both sides of the body equally, with the
worse symptoms in the hands and feet, rather than in the hip or shoulders.

It is important to note that patients with cancer can develop peripheral
neuropathy as a result of other complications of cancer, or from side-effects of
the cancer treatments. The cancers most often associated with paraneoplastic
neuropathies are lung cancer, myeloma, B-cell lymphoma, and Waldenstrom’s
macroglobulinemia. Only a small number of patients have paraneoplastic
neuropathies with associated antibodies. The two antibodies that are associated
with this PNS are “anti-Hu” and “anti-CV2/CRMP5;” patients with these antibodies
often have lung cancer.

Vasculitis of the Nerve and Muscle
This is a very rare disorder that consists of inflammation of the small blood
vessels of the peripheral nerves and muscles. Patients often develop symptoms of
peripheral neuropathy that may initially affect only one arm or leg before
involving both sides. Pain often occurs.

Several types of tumors have been associated with this type of paraneoplastic
neurologic syndrome, including cancers of the lung, kidney, prostate and
lymphomas. There are no specific paraneoplastic antibodies associated with this
disorder.

Lambert Eaton Myasthenic Syndrome (LEMS)

This disorder results from impaired release of the neurotransmitter
acetylcholine. Because of this deficit, the muscles do not contract well,
causing weakness that usually presents in the hips and shoulders. A transient
drooping of the eyelids (ptosis) and double vision (diplopia) can occur. The
muscles of the neck, and sometimes, the respiratory muscles that control
breathing, can be affected.

LEMS is also associated with symptoms of autonomic nervous system dysfunction,
including dry mouth, rapid decrease of blood pressure on standing up
(orthostatic hypotension), constipation, difficulty controlling bladder
dysfunction, and erectile dysfunction.

Patients with LEMS have antibodies called voltage-gated calcium channel (VGCC)
antibodies. However, it should be noted that the VGCC antibodies do not indicate
that the specific cause of LEMS is paraneoplastic, as the disorder can occur in
the absence of cancer. Approximately 60% of all patients with LEMS have
small-cell lung cancer.

Myasthenia Gravis (MG)

This is a well-known disorder of the neuromuscular junction. The symptoms of MG
may resemble those of patients with LEMS, but the muscles of the eyes, eyelids,
face, swallowing, speech and respiratory muscles are more frequently and
severely involved.

In contrast to LEMS, in which many patients have cancer, only 10-15% of patients
with myasthenia gravis have a tumor, in which case it is in the thymus gland
(thymoma). While there is an antibody associated with myasthenia gravis (AChR
antibodies), this is not a paraneoplastic antibody.

Polymyositis/Dermatomyositis

These are two different disorders of the muscle. The term “myositis” means
inflammation in the muscle. “Polymyositis” means that multiple muscles are
affected by the inflammation. “Dermatomyositis” means that in addition to the
muscles, there is also involvement of the skin.

Both disorders cause similar muscle symptoms, including pain or soreness of the
shoulders and thighs, along with weakness. The weakness predominantly affects
the hips and shoulders, and can also affect the neck, causing difficulty in
holding the head up, and muscles of the throat and esophagus causing difficulty
swallowing. Inflammation of the heart (myocarditis), joints (arthralgias), and
lungs (interstitial lung disease) can occur.

Patients with dermatomyositis develop skin changes usually characterized by a
purplish discoloration of the eyelids (heliotrope rash) with swelling. In
addition, a crusty red rash can occur over the knuckles. Some patients develop
itchiness and ulcerations in the skin.

Most patients with polymyositis do not have an associated cancer, so this
disorder is rarely paraneoplastic. However, dermatomyositis is more likely to be
associated with a malignant tumor. There are several tumors that can be
involved, including but not limited to lung, breast, ovary, and gastrointestinal
tract tumors. It has been shown that patients with dermatomyositis positive for
either anti-transcriptional intermediary factor 1-gamma or anti-nuclear matrix
protein 2 antibodies have increased risk of having cancer.

Necrotizing Autoimmune Myopathy

This is a disease that associates with prominent muscle weakness at the level of
the shoulders and hips. The muscle destruction (necrosis) is more prominent than
the presence of inflammation. There are several antibodies that have been
reported in patients with this disease including
anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and anti-signal
recognition particle (SRP). Studies have shown that patients without antibodies
or with antibodies against HMGCR are more likely to have an associated cancer
than patients with antibodies against SRP. No specific type of cancer was found
to predominate.

CAUSES

The specific cause of PNS is unknown. The findings in the serum or cerebrospinal
fluid (CSF) of antibodies (onconeural antibodies) to specific malignant tumors
suggest that the cause of some PNS is the immune response against the tumor
being misdirected against the nervous system.

AFFECTED POPULATIONS

In general, PNS are considered rare disorders. However, some PNS such as the
paraneoplastic neuropathies are relatively frequent, affecting approximately 10%
of patients with some cancers of the immunological system. In many instances,
PNS are not recognized and the patients’ complaints attributed to other more
common problems.

PNS affect males and females in equal numbers. In general PNS are more common in
older patients as they more frequently develop those cancers associated with
PNS. However, PNS can occur in children and teenagers and as noted above there
are some PNS (e.g., paraneoplastic anti-NMDAR encephalitis) that more commonly
affect younger patients.

DIAGNOSIS

Patients with a suspected paraneoplastic syndrome should receive a complete
panel of laboratory studies, including blood, urine, and CSF. In addition, the
use of an MRI, EEG (electroencephalogram), and EMG (electromyogram) can further
display abnormalities that help to diagnose PNS.

Many (but not all) patients with PNS have paraneoplastic antibodies in their
blood and/or CSF. If any of these antibodies are identified, then the diagnosis
of PNS is strongly supported or definite (depending on the type of antibody).

It should be understood that there are three types of antibodies that associate
with neurological syndromes. There is one type that associates with specific
neurological syndromes but not with cancer. Another type includes antibodies
that almost always associate with the presence of cancer. The third type of
antibodies includes those that may occur with or without cancer. Therefore, it
is important to understand the relative value of each category of antibodies in
suggesting that the neurological syndrome is paraneoplastic or not.

Once a diagnosis of or a suspicion of a paraneoplastic syndrome is apparent,
other tests are used to identify the location and type of tumor. These include
CT scanning (usually of the chest, abdomen, and pelvis), mammography,
ultrasound, PET scan, and blood tests for specific tumor markers (such as the
CA125, for ovarian cancer). The type of paraneoplastic antibody often helps to
direct the search of the tumor to a specific organ (for example, most patients
with Hu antibodies have lung cancer).

STANDARD THERAPIES

Treatment

Except for a few PNS of the peripheral nerves and neuromuscular junction, there
is no general consensus yet for treating many of these syndromes. However, there
are several principles in which most investigators agree upon:

The tumor is the main trigger for all PNS. Therefore, in general, prompt
identification and treatment of the tumor is essential. Thus, the first
therapeutic option is usually surgery, radiation, or chemotherapy (singly or in
combination).

Because many PNS are immune-mediated, immunotherapy should be considered based
on the type of antibody involved. PNS in which the antibody attacks the
cell-surface of neurons respond better to immunotherapies than PNS in which the
antibodies react with proteins that are inside the neurons (or intracellular
antigens).

The usage, timing, and type of immunotherapy will vary depending on the specific
type of PNS and/or whether the tumor is being treated at the same time.

In a patient who has been in remission from a cancer treated within the prior
five years, symptoms that appear to be a PNS imply a high likelihood of tumor
recurrence. Repeat cancer screening should be undertaken.

Similarly, a relapse or sudden worsening of neurological symptoms in a patient
known to have a PNS, but whose cancer was thought to be in remission, should
raise a high index of suspicion for cancer recurrence.

INVESTIGATIONAL THERAPIES

Clinical research on PNS is being conducted at the University of Pennsylvania,
Department of Neurology, USA and the Biomedical Research Institute, University
of Barcelona, Spain.

For information, contact:
Josep Dalmau, MD, PhD
Department of Neurology
Research Assistant: Lindsey McCracken (mccracken@uphs.upenn.edu)
University of Pennsylvania
3400 Spruce Street, Philadelphia, PA 19104
Phone: 215-746-8511
Fax: 215-746-9122
Website: https://www.pennmedicine.org/providers/profile/josep-dalmau

and

ICREA-IDIBAPS, Service of Neurology, Hospital Clinic
Research Assistant: Maria Rodes (Marodes@clinic.ub.es)
University of Barcelona
Neuroimmunology Lab P3A
c/ Casanova, 143
Barcelona 08036 (Spain)
Phone: +34 932 271 738
Fax: +34 932 271 726

Information on current clinical trials is posted on the Internet at
www.clinicaltrials.gov . All studies receiving U.S. government funding, and some
supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center
in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:
www.centerwatch.com

For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/

RESOURCES

RareConnect offers a safe patient-hosted online community for patients and
caregivers affected by this rare disease. For more information,
visit www.rareconnect.org.

SUPPORTING ORGANIZATIONS

* Cancer Support Community
* 1050 17th St NW Suite 500
* Washington, DC 20036
* Phone: (202) 659-9709
* Toll-free: (888) 793-9355
* Website: http://www.cancersupportcommunity.org/
* Genetic and Rare Diseases (GARD) Information Center
* PO Box 8126
* Gaithersburg, MD 20898-8126
* Phone: (301) 251-4925
* Toll-free: (888) 205-2311
* Website: http://rarediseases.info.nih.gov/GARD/
* National Cancer Institute
* 6116 Executive Blvd Suite 300
* Bethesda, MD 20892-8322 USA
* Phone: (301) 435-3848
* Toll-free: (800) 422-6237
* Email: cancergovstaff@mail.nih.gov
* Website: http://www.cancer.gov
* NIH/National Institute of Neurological Disorders and Stroke
* P.O. Box 5801
* Bethesda, MD 20824
* Phone: (301) 496-5751
* Toll-free: (800) 352-9424
* Website: http://www.ninds.nih.gov/

REFERENCES

JOURNAL ARTICLES
Allenbach Y, Keraen J, Bouvier A-M, et al. High risk of cancer in autoimmune
necrotizing myopathies: usefulness of myositis specific antibody. Brain
2016;139;2131-2135.

Graus F, Titulaer MJ, Balu R, et al. Clinical approach to diagnosis of
autoimmune encephalitis. Lancet Neurol 2016;15:391-404.

Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors
for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor
encephalitis: a cohort study. Lancet Neurol 2013;12:157-165.

Titulaer MJ, McCracken L, Gabilondo I, et al. Late-onset
anti-N-methyl-D-aspartate receptor encephalitis. Neurology 2013;81:1058-1063.

Titulaer, MJ, Soffietti R, Dalmau J, et al. Screening for malignancies in
paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol.
2011;18:19-e3.

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R.
Experience and investigations on anti-NMDA receptor encephalitis. Lancet Neurol.
2011;10:63-74.

Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to
synaptic and neuronal cell surface proteins. Neurology. 2011;77:179-189.

McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission
tomography-computed tomography in paraneoplastic neurologic disorders:
systematic analysis and review. Arch Neurol. 2010;67:322-329.

Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol.
2008;7:327-340.

Antoine JC, Camdessanche JP. Peripheral nervous system involvement in patients
with cancer. Lancet Neurol. 2007;6:75-86.

Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system.
Semin Oncol. 2006;33:270-298.

Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr
Opin Neurol. 2005;18:598-603.

Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for
paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry.
2004;75:1135-1140.

YEARS PUBLISHED

2007, 2012, 2016

The information in NORD’s Rare Disease Database is for educational purposes only
and is not intended to replace the advice of a physician or other qualified
medical professional.

The content of the website and databases of the National Organization for Rare
Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or
disseminated, in any way, for any commercial or public purpose, without prior
written authorization and approval from NORD. Individuals may print one hard
copy of an individual disease for personal use, provided that content is
unmodified and includes NORD’s copyright.

National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100

REPORT INDEX

General Discussion

Signs & Symptoms

Causes

Affected Populations

Standard Therapies

Investigational Therapies

Resources

Supporting Organizations

References

rarediseases.org Open in urlscan Pro 141.193.213.20 Public Scan

Form analysis 1 forms found in the DOM

GET /

Text Content

rarediseases.org Open in urlscan Pro
141.193.213.20 Public Scan

Form analysis
1 forms found in the DOM